• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

酪氨酸激酶抑制剂对表皮生长因子受体酪氨酸激酶活性的抑制动力学及用新计算机程序进行的分析

Kinetics of inhibition by tyrphostins of the tyrosine kinase activity of the epidermal growth factor receptor and analysis by a new computer program.

作者信息

Posner I, Engel M, Gazit A, Levitzki A

机构信息

Department of Biological Chemistry, Hebrew University of Jerusalem, Israel.

出版信息

Mol Pharmacol. 1994 Apr;45(4):673-83.

PMID:8183246
Abstract

The kinetics of inhibition of the epidermal growth factor (EGF) receptor (EGFR) tyrosine kinase (TK) activity by erbstatin, tyrphostins, and lavendustin derivatives were studied in a system that employs poly(Glu6Ala3Tyr) (GAT) and ATP as substrates, after preactivation with EGF. All data were analyzed for computer best-fit curves by a program that was written for this purpose and is available upon request to those interested. The inhibition kinetics followed a sequential, Bi-Bi, rapid equilibrium, random mechanism, the mechanism of the EGFR-TK. Erbstatin and a few tyrphostins that contain a 3,4-dihydroxy-(cis)-cinnamonitrile [1-(3',4'-dihydroxyphenyl)-2-nitriloethene] group were found to be pure competitive inhibitors with respect to both substrates of the kinase reaction, i.e., GAT and ATP. Two tyrphostins, each containing an additional dihydroxyphenyl group in the alpha-position, were found to be pure competitive inhibitors with respect to GAT and noncompetitive (or mixed-competitive) inhibitors with respect to ATP. A lavendustin derivative with a 2,5-dihydroxyphenyl ring and a lavendustin derivative with a 3,4-dihydroyphenyl ring were also found to be competitive inhibitors with respect to both ATP and GAT. Various possible modes of binding at the EGFR-TK active center for the tyrphostins studied are proposed and the significance of the present findings, as well as the interpretations of computer analyses of kinetic data, is discussed.

摘要

在使用聚(Glu6Ala3Tyr)(GAT)和ATP作为底物的体系中,在表皮生长因子(EGF)预激活后,研究了埃伯司他汀、 tyrphostins和拉文达斯汀衍生物对表皮生长因子受体(EGFR)酪氨酸激酶(TK)活性的抑制动力学。所有数据均通过为此编写的程序进行计算机最佳拟合曲线分析,感兴趣者可索取该程序。抑制动力学遵循一种顺序、双底物、快速平衡、随机机制,即EGFR-TK的机制。发现埃伯司他汀和一些含有3,4-二羟基-(顺式)-肉桂腈[1-(3',4'-二羟基苯基)-2-腈基乙烯]基团的tyrphostins是激酶反应两种底物(即GAT和ATP)的纯竞争性抑制剂。发现两种tyrphostins,每种在α位含有一个额外的二羟基苯基,对GAT是纯竞争性抑制剂,对ATP是非竞争性(或混合竞争性)抑制剂。还发现一种具有2,5-二羟基苯基环的拉文达斯汀衍生物和一种具有3,4-二羟基苯基环的拉文达斯汀衍生物对ATP和GAT都是竞争性抑制剂。提出了所研究的tyrphostins在EGFR-TK活性中心的各种可能结合模式,并讨论了本研究结果的意义以及动力学数据计算机分析的解释。

相似文献

1
Kinetics of inhibition by tyrphostins of the tyrosine kinase activity of the epidermal growth factor receptor and analysis by a new computer program.酪氨酸激酶抑制剂对表皮生长因子受体酪氨酸激酶活性的抑制动力学及用新计算机程序进行的分析
Mol Pharmacol. 1994 Apr;45(4):673-83.
2
The degree of inhibition of protein tyrosine kinase activity by tyrphostin 23 and 25 is related to their instability.酪氨酸磷酸化抑制剂23和25对蛋白质酪氨酸激酶活性的抑制程度与其不稳定性有关。
Cancer Res. 1994 Feb 15;54(4):867-9.
3
Inhibition of platelet-derived growth factor and epidermal growth factor receptor signaling events after treatment of cells with specific synthetic inhibitors of tyrosine kinase phosphorylation.用酪氨酸激酶磷酸化的特异性合成抑制剂处理细胞后,血小板衍生生长因子和表皮生长因子受体信号转导事件受到抑制。
J Pharmacol Exp Ther. 1998 May;285(2):844-52.
4
Synthesis and antiproliferative activity of tyrphostins containing heteroaromatic moieties.
Anticancer Drug Des. 1994 Aug;9(4):291-309.
5
Antiproliferative effect of tyrosine kinase inhibitors in epidermal growth factor-stimulated growth of human gastric cancer cells.酪氨酸激酶抑制剂对表皮生长因子刺激的人胃癌细胞生长的抗增殖作用。
Anticancer Res. 1993 Nov-Dec;13(6A):2119-23.
6
Activation of the epidermal growth factor receptor by skin tumor promoters and in skin tumors from SENCAR mice.皮肤肿瘤启动子及SENCAR小鼠皮肤肿瘤中表皮生长因子受体的激活
Cell Growth Differ. 1995 Nov;6(11):1447-55.
7
Antiproliferative effects of tyrosine kinase inhibitors (tyrphostins) on human bladder and renal carcinoma cells.酪氨酸激酶抑制剂( tyrphostins )对人膀胱癌细胞和肾癌细胞的抗增殖作用。
J Surg Res. 1995 Dec;59(6):675-80. doi: 10.1006/jsre.1995.1222.
8
Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors.基于受体引导比对的苄叉丙二腈酪氨酸磷酸化抑制剂作为表皮生长因子受体(EGFR)和人表皮生长因子受体2(HER-2)激酶抑制剂的3D-QSAR研究
J Med Chem. 2003 Oct 23;46(22):4657-68. doi: 10.1021/jm030065n.
9
Receptor tyrosine kinase inhibition suppresses growth of pediatric renal tumor cells in vitro.受体酪氨酸激酶抑制在体外抑制小儿肾肿瘤细胞的生长。
J Pediatr Surg. 2000 Jun;35(6):884-90. doi: 10.1053/jpsu.2000.6907.
10
Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation.辐射诱导的人A431鳞状癌细胞增殖依赖于表皮生长因子受体(EGFR)酪氨酸磷酸化。
Oncogene. 1997 Sep 4;15(10):1191-7. doi: 10.1038/sj.onc.1201275.

引用本文的文献

1
Peripheral Neuropathy under Oncologic Therapies: A Literature Review on Pathogenetic Mechanisms.肿瘤治疗相关周围神经病:发病机制的文献综述。
Int J Mol Sci. 2021 Feb 17;22(4):1980. doi: 10.3390/ijms22041980.
2
Expression Patterns of CD44 and AREG Under Treatment With Selective Tyrosine Kinase Inhibitors in HPV and HPV Squamous Cell Carcinoma.CD44 和 AREG 在 HPV 和 HPV 鳞状细胞癌中经选择性酪氨酸激酶抑制剂治疗后的表达模式。
Cancer Genomics Proteomics. 2020 Sep-Oct;17(5):579-585. doi: 10.21873/cgp.20214.
3
Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors.
非小细胞肺癌治疗的靶向疗法:单克隆抗体与生物抑制剂
Hum Vaccin Immunother. 2017 Apr 3;13(4):843-853. doi: 10.1080/21645515.2016.1249551. Epub 2016 Nov 10.
4
The epidermal growth factor receptor pathway in chronic kidney diseases.慢性肾脏病中的表皮生长因子受体通路。
Nat Rev Nephrol. 2016 Aug;12(8):496-506. doi: 10.1038/nrneph.2016.91. Epub 2016 Jul 4.
5
Targeting HER (ERBB) signaling in head and neck cancer: An essential update.靶向头颈部癌中的HER(ERBB)信号传导:重要更新
Mol Aspects Med. 2015 Nov;45:74-86. doi: 10.1016/j.mam.2015.07.001. Epub 2015 Jul 7.
6
Defining the role of tyrosine kinase inhibitors in early stage non-small cell lung cancer.确定酪氨酸激酶抑制剂在早期非小细胞肺癌中的作用。
J Cancer. 2015 May 7;6(6):568-74. doi: 10.7150/jca.11893. eCollection 2015.
7
Small molecule substrate phosphorylation site inhibitors of protein kinases: approaches and challenges.蛋白激酶的小分子底物磷酸化位点抑制剂:方法与挑战
ACS Chem Biol. 2015 Jan 16;10(1):175-89. doi: 10.1021/cb5008376. Epub 2014 Dec 23.
8
Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC).透明细胞肾细胞癌(ccRCC)中对酪氨酸激酶抑制剂获得性耐药的机制
Curr Signal Transduct Ther. 2014 Dec;8(3):218-228. doi: 10.2174/1574362409666140206223014.
9
Therapeutic destruction of insulin receptor substrates for cancer treatment.治疗性破坏胰岛素受体底物用于癌症治疗。
Cancer Res. 2013 Jul 15;73(14):4383-94. doi: 10.1158/0008-5472.CAN-12-3385. Epub 2013 May 7.
10
A homogeneous, high-throughput assay for phosphatidylinositol 5-phosphate 4-kinase with a novel, rapid substrate preparation.一种新型的、快速的底物制备方法,用于均相、高通量的磷脂酰肌醇 5-磷酸 4-激酶分析。
PLoS One. 2013;8(1):e54127. doi: 10.1371/journal.pone.0054127. Epub 2013 Jan 10.